You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
賽託生物(300583.SZ):子公司收到地塞米松原料藥歐洲CEP證書
格隆匯 06-18 16:22

格隆匯6月18日丨賽託生物(300583.SZ)公佈,公司控股子公司山東斯瑞藥業有限公司(簡稱“斯瑞藥業”)近日收到歐洲藥品質量管理局(簡稱“EDQM”)簽發的原料藥歐洲藥典適用性證書(以下簡稱“CEP證書”)。

地塞米松原料藥可以用於生產地塞米松相關劑型藥品,地塞米松是一種人工合成的長效腎上腺皮質激素類藥物,具有強大的抗炎、抗過敏、抗休克及免疫抑制作用。臨牀常用於治療類風濕性關節炎、系統性紅斑狼瘡等自身免疫性疾病,過敏性疾病(如嚴重的支氣管哮喘、皮炎),以及某些急性感染性疾病的輔助治療(需與抗菌藥物合用),還可用於預防化療藥物引起的嘔吐等。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account